Immunology

Boroproline compound demonstrates peptide adjuvant activity

Published in Vaccine Weekly, May 26th, 2004

Point Therapeutics, Inc., (POTP) announced the presentation of study data on one of the company's boroproline compounds (PT-100), indicating adjuvant properties to antigenic peptides in preclinical models of peptide vaccination.

PT-100, which represents one of a family of compounds, appears to induce robust CD4+ and CD8+ T cell responses and potentially provide durable immunity.

"I am pleased to announce the initiation of the company's second development program," said Don Kiepert, president and chief executive officer at Point Therapeutics.

"This preclinical program is in addition to our oncology program, where PT-100 is...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2004-05-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry